A stock in the biotechnology and drugs complex that's setting up for a near-term breakout trade is (HEB), which is engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. This stock has been on fire so far in 2012, with shares up around 380%.
This company has a major catalyst on the horizon, since it will meet with the FDA on Feb. 1, 2013, for the possible approval of its drug Ampligen, which treats chronic fatigue syndrome. This stock has already started to run-up ahead of that catalyst, but there could be plenty more upside where that came from.
If you take a look at the chart for Hemispherx BioPharma, you'll notice that this stock has been uptrending very strong for the last three months, with shares soaring from a low of 25 cents to its recent high of 96 cents. During that uptrend, shares of HEB have been consistently making higher lows and higher highs, which is bullish technical price action. That move has also been accompanied by heavy upside volume, especially during the last month and a half. Shares of HEB are quickly moving within range of triggering a near-term breakout trade.Market players should now look for long-biased trades in HEB if it can manage to take out some near-term overhead resistance levels at 95 cents to $1.01 a share with high volume. Look for a sustained move or close above those levels with volume that tracks in close to or above its three-month average action of 1.3 million shares. If that breakout triggers soon, then HEB will have a great chance of doubling and hitting $2 a share. One can look to buy HEB off any weakness and anticipate that breakout and simply use a stop that sits right around some near-term support at 75 cents to 72 cents per share. One could also buy off strength once HEB clears 95 cents to $1.01 a share with volume, and then simply use a stop at around 90 cents to 88 cents per share.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV